<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02134990</url>
  </required_header>
  <id_info>
    <org_study_id>OS-LC-P2a-01</org_study_id>
    <nct_id>NCT02134990</nct_id>
  </id_info>
  <brief_title>Oshadi D and Oshadi R in Combination With Docetaxel, as 2nd Line Therapy for Metastatic Non Small Cell Lung Cancer</brief_title>
  <official_title>A Phase IIa, Open-Label, Single- Center Study to Assess the Activity of Oshadi D and Oshadi R in Combination With Docetaxel, as 2nd Line Therapy for Metastatic Non Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oshadi Drug Administration</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oshadi Drug Administration</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will be a prospective open-label single-center study in previously treated patients&#xD;
      with Non Small Cell Lung Cancer (NSCLC). Treatment efficacy and safety of the combination of&#xD;
      Oshadi D and Oshadi R with Docetaxel will be will be evaluated.&#xD;
&#xD;
      Patients will receive Docetaxel in combination with Oshadi D and Oshadi R. Patient will be&#xD;
      evaluated throughout the study for safety and tolerance to multiple dose regimens of Oshadi D&#xD;
      and Oshadi R.&#xD;
&#xD;
      CT or MRI imaging will be performed prior to treatment initiation and at the end of every 3&#xD;
      Docetaxel cycles (12 weeks). In case of disease progression, dose augmentation will be&#xD;
      considered or subsequent therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">June 2014</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival time</measure>
    <time_frame>12 months</time_frame>
    <description>overall survival of the patient</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events and serious adverse events occurence</measure>
    <time_frame>One month following treatment initiation</time_frame>
    <description>Adverse events and serious adverse events occurred during the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient report outcome</measure>
    <time_frame>12 months</time_frame>
    <description>To assess patients quality of life by QLC30 questionnaire</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>12 months</time_frame>
    <description>time from treatment initiation to documentation of disease progression or death)</description>
  </other_outcome>
  <other_outcome>
    <measure>Duration of Response (DoR);</measure>
    <time_frame>12 months</time_frame>
    <description>response duration to the drug</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in tumor size</measure>
    <time_frame>12 weeks</time_frame>
    <description>changes in tumor size</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <arm_group>
    <arm_group_label>Oshadi D and Oshadi R with Docetaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oshadi D and Oshadi R anti cancer agents with Docetaxol chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oshadi D and Oshadi R</intervention_name>
    <description>Anti cancer agents</description>
    <arm_group_label>Oshadi D and Oshadi R with Docetaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Chemotheraphy</description>
    <arm_group_label>Oshadi D and Oshadi R with Docetaxel</arm_group_label>
    <other_name>Taxoter</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Locally advanced or metastatic NSCLC (IIIB-IV)&#xD;
&#xD;
          -  Failure of first line anti-cancer therapy (either radiological documentation of&#xD;
             disease progression or due to toxicity) in advanced disease or subsequent relapse of&#xD;
             disease following first line therapy&#xD;
&#xD;
          -  Man or woman 21 years and above&#xD;
&#xD;
          -  Adequate performance status (ECOG 0, and 1)&#xD;
&#xD;
          -  Patient must have adequate organ function&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Females of childbearing potential and males must be willing to use an effective method&#xD;
             of contraception (hormonal or barrier method of birth control; abstinence) from the&#xD;
             time consent is signed until 6 weeks after treatment discontinuation.&#xD;
&#xD;
          -  Females of childbearing potential must have a negative pregnancy test within 7 days&#xD;
             prior to being registered for protocol therapy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any treatment with investigational agent within 10 days prior to registration for&#xD;
             protocol therapy.&#xD;
&#xD;
          -  Cerebrovascular accident, transient ischemic attack or myocardial infarction within 3&#xD;
             months prior to registration for protocol therapy.&#xD;
&#xD;
          -  Evidence of pulmonary embolism within 3 months prior to registration for protocol&#xD;
             therapy.&#xD;
&#xD;
          -  Any history of hematologic malignancies.&#xD;
&#xD;
          -  Patient with known positive HIV serology at screening.&#xD;
&#xD;
          -  Female patient who are breastfeeding or have a positive pregnancy test at screening or&#xD;
             at any time during the study.&#xD;
&#xD;
          -  Uncontrolled hypertension (&gt;160/100 mm Hg despite optimal medical therapy).&#xD;
&#xD;
          -  Evidence of ongoing cardiac dysrhythmias of NCI CTCAE (Common Toxicity Criteria for&#xD;
             Adverse Effects) Version 3.0 grade 2.&#xD;
&#xD;
          -  Patients in whom radiation or surgery is indicated&#xD;
&#xD;
          -  Significant swallowing disorders.&#xD;
&#xD;
          -  Small bowel surgery.&#xD;
&#xD;
          -  Suspicion of absorption disruption as a result of abdominal radiation&#xD;
&#xD;
          -  Pre-existing mal absorption syndrome, irritable bowel syndrome or other clinical&#xD;
             situation which could affect oral absorption.&#xD;
&#xD;
          -  Evidence of concurrent (&lt; 5 years) second malignancy&#xD;
&#xD;
          -  Mental disorders.&#xD;
&#xD;
          -  Inability to give written informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hovav Nehushtan, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hadassah Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hanna Levy, Dr.</last_name>
    <phone>+972-52-2824966</phone>
    <email>hanna@oshadi-da.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hadassah Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hanna Levy, Dr.</last_name>
      <phone>+972-52-2824966</phone>
      <email>hanna@oshadi-da.com</email>
    </contact>
    <investigator>
      <last_name>Hovav Nehushtan, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>May 7, 2014</study_first_submitted>
  <study_first_submitted_qc>May 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 9, 2014</study_first_posted>
  <last_update_submitted>April 16, 2018</last_update_submitted>
  <last_update_submitted_qc>April 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Carcinoma, Non-Small-Cell Lung</keyword>
  <keyword>Docetaxel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

